{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:38:43Z","timestamp":1792640323849,"version":"4.5.0"},"reference-count":186,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Multiple myeloma (MM) is a heterogeneous plasma cell malignancy differing substantially in clinical behavior, prognosis, and response to treatment. With the advent of novel therapies, many patients achieve long-lasting remissions, but some experience aggressive and treatment refractory relapses. So far, MM is considered incurable. Myeloma pathogenesis can broadly be explained by two interacting mechanisms, intraclonal evolution of cancer cells and development of an immunosuppressive tumor microenvironment. Failures in isotype class switching and somatic hypermutations result in the neoplastic transformation typical of MM and other B cell malignancies. Interestingly, although genetic alterations occur and evolve over time, they are also present in premalignant stages, which never progress to MM, suggesting that genetic mutations are necessary but not sufficient for myeloma transformation. Changes in composition and function of the immune cells are associated with loss of effective immune surveillance, which might represent another mechanism driving malignant transformation. During the last decade, the traditional view on myeloma treatment has changed dramatically. It is increasingly evident that treatment strategies solely based on targeting intrinsic properties of myeloma cells are insufficient. Lately, approaches that redirect the cells of the otherwise suppressed immune system to take control over myeloma have emerged. Evidence of utility of this principle was initially established by the observation of the graft-versus-myeloma effect in allogeneic stem cell-transplanted patients. A variety of new strategies to harness both innate and antigen-specific immunity against MM have recently been developed and intensively tested in clinical trials. This review aims to give readers a basic understanding of how the immune system can be engaged to treat MM, to summarize the main immunotherapeutic modalities, their current role in clinical care, and future prospects.<\/jats:p>","DOI":"10.3390\/cancers13184546","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T10:31:34Z","timestamp":1631269894000},"page":"4546","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Harnessing the Immune System to Fight Multiple Myeloma"],"prefix":"10.3390","volume":"13","author":[{"given":"Jakub","family":"Krejcik","sequence":"first","affiliation":[{"name":"Centre for Cellular Immunotherapy of Haematological Cancer Odense (CITCO), Odense University Hospital, 5000 Odense, Denmark"},{"name":"Department of Haematology, Odense University Hospital, 5000 Odense, Denmark"},{"name":"Haematology Research Unit, Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5892-1174","authenticated-orcid":false,"given":"Mike Bogetofte","family":"Barnkob","sequence":"additional","affiliation":[{"name":"Centre for Cellular Immunotherapy of Haematological Cancer Odense (CITCO), Odense University Hospital, 5000 Odense, Denmark"},{"name":"Department of Clinical Immunology, Odense University Hospital, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Guldborg","family":"Nyvold","sequence":"additional","affiliation":[{"name":"Centre for Cellular Immunotherapy of Haematological Cancer Odense (CITCO), Odense University Hospital, 5000 Odense, Denmark"},{"name":"Haematology Research Unit, Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark"},{"name":"Haematology-Pathology Research Laboratory, Research Unit for Haematology and Research Unit for Pathology, University of Southern Denmark and Odense University Hospital, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Stauffer","family":"Larsen","sequence":"additional","affiliation":[{"name":"Centre for Cellular Immunotherapy of Haematological Cancer Odense (CITCO), Odense University Hospital, 5000 Odense, Denmark"},{"name":"Department of Haematology, Odense University Hospital, 5000 Odense, Denmark"},{"name":"Haematology Research Unit, Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6968-148X","authenticated-orcid":false,"given":"Torben","family":"Barington","sequence":"additional","affiliation":[{"name":"Centre for Cellular Immunotherapy of Haematological Cancer Odense (CITCO), Odense University Hospital, 5000 Odense, Denmark"},{"name":"Department of Clinical Immunology, Odense University Hospital, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Abildgaard","sequence":"additional","affiliation":[{"name":"Centre for Cellular Immunotherapy of Haematological Cancer Odense (CITCO), Odense University Hospital, 5000 Odense, Denmark"},{"name":"Department of Haematology, Odense University Hospital, 5000 Odense, Denmark"},{"name":"Haematology Research Unit, Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,10]]},"reference":[{"key":"ref_1","first-page":"232546","article-title":"Implications of Heterogeneity in Multiple Myeloma","volume":"2014","author":"Lim","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1158\/1078-0432.CCR-10-1822","article-title":"From Myeloma Precursor Disease to Multiple Myeloma: New Diagnostic Concepts and Opportunities for Early Intervention","volume":"17","author":"Landgren","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","article-title":"MGUS to Myeloma: A Mysterious Gammopathy of Underexplored Significance","volume":"128","author":"Dhodapkar","year":"2016","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3324\/haematol.2017.163766","article-title":"The Spectrum of Somatic Mutations in Monoclonal Gammopathy of Undetermined Significance Indicates a Less Complex Genomic Landscape than That in Multiple Myeloma","volume":"102","author":"Mikulasova","year":"2017","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The Genetic Architecture of Multiple Myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00262-004-0607-8","article-title":"Harnessing Host Immune Responses to Preneoplasia: Promise and Challenges","volume":"54","author":"Dhodapkar","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.4202","article-title":"Microenvironment-Dependent Growth of Preneoplastic and Malignant Plasma Cells in Humanized Mice","volume":"22","author":"Das","year":"2016","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1172\/JCI77181","article-title":"Immunosurveillance and Therapy of Multiple Myeloma Are CD226 Dependent","volume":"125","author":"Guillerey","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"198539","DOI":"10.1155\/2014\/198539","article-title":"Immunological Dysregulation in Multiple Myeloma Microenvironment","volume":"2014","author":"Romano","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"D\u00edaz-Tejedor, A., Lorenzo-Mohamed, M., Puig, N., Garc\u00eda-Sanz, R., Mateos, M.-V., Garayoa, M., and Pa\u00edno, T. (2021). Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression. Cancers, 13.","DOI":"10.3390\/cancers13061353"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fonc.2020.00636","article-title":"Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities","volume":"10","author":"Leblay","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","article-title":"Elevated IL-17 Produced by Th17 Cells Promotes Myeloma Cell Growth and Inhibits Immune Function in Multiple Myeloma","volume":"115","author":"Prabhala","year":"2010","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2141.2004.04984.x","article-title":"Either Interleukin-12 or Interferon-\u03b3 Can Correct the Dendritic Cell Defect Induced by Transforming Growth Factor \u03921 in Patients with Myeloma","volume":"125","author":"Brown","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1182\/blood.V126.23.502.502","article-title":"Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma","volume":"126","author":"Kawano","year":"2015","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Muthu Raja, K.R., Rihova, L., Zahradova, L., Klincova, M., Penka, M., and Hajek, R. (2012). Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple Myeloma. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047077"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.2019004537","article-title":"Immunogenomic Identification and Characterization of Granulocytic Myeloid-Derived Suppressor Cells in Multiple Myeloma","volume":"136","author":"Perez","year":"2020","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Andersen, M.N., Andersen, N.F., Lauridsen, K.L., Etzerodt, A., Sorensen, B.S., Abildgaard, N., Plesner, T., Hokland, M., and M\u00f8ller, H.J. (2021). STAT3 Is Over-Activated within CD163pos Bone Marrow Macrophages in Both Multiple Myeloma and the Benign Pre-Condition MGUS. Cancer Immunol. Immunother.","DOI":"10.1007\/s00262-021-02952-1"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.3109\/10428194.2013.778409","article-title":"Macrophages in Multiple Myeloma: Emerging Concepts and Therapeutic Implications","volume":"54","author":"Asimakopoulos","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.3389\/fimmu.2018.02431","article-title":"Update on PD-1\/PD-L1 Inhibitors in Multiple Myeloma","volume":"9","author":"Jelinek","year":"2018","journal-title":"Front. Immunol"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Sun, J., Muz, B., Alhallak, K., Markovic, M., Gurley, S., Wang, Z., Guenthner, N., Wasden, K., Fiala, M., and King, J. (2020). Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma. Cancers (Basel), 12.","DOI":"10.3390\/cancers12020305"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT Immune Checkpoint Blockade Restores CD8+ T-Cell Immunity against Multiple Myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00262-011-1040-4","article-title":"Ectonucleotidases CD39 and CD73 on OvCA Cells Are Potent Adenosine-Generating Enzymes Responsible for Adenosine Receptor 2A-Dependent Suppression of T Cell Function and NK Cell Cytotoxicity","volume":"60","author":"Strohschein","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2119\/molmed.2016.00198","article-title":"Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma","volume":"22","author":"Horenstein","year":"2016","journal-title":"Mol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1158\/0008-5472.CAN-15-1320","article-title":"Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment","volume":"75","author":"Ponzetta","year":"2015","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8444","DOI":"10.1158\/0008-5472.CAN-06-4230","article-title":"The Requirement for DNAM-1, NKG2D, and NKp46 in the Natural Killer Cell-Mediated Killing of Myeloma Cells","volume":"67","author":"Meade","year":"2007","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2004-04-1422","article-title":"HLA Class I, NKG2D, and Natural Cytotoxicity Receptors Regulate Multiple Myeloma Cell Recognition by Natural Killer Cells","volume":"105","author":"Carbone","year":"2005","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Pazina, T., MacFarlane, A.W., Bernabei, L., Dulaimi, E., Kotcher, R., Yam, C., Bezman, N.A., Robbins, M.D., Ross, E.A., and Campbell, K.S. (2021). Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13020226"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3389\/fimmu.2017.01444","article-title":"Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs","volume":"8","author":"Pittari","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"599098","DOI":"10.3389\/fonc.2020.599098","article-title":"Actors on the Scene: Immune Cells in the Myeloma Niche","volume":"10","author":"Leone","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3324\/haematol.2018.200881","article-title":"Allogeneic Transplantation of Multiple Myeloma Patients May Allow Long-Term Survival in Carefully Selected Patients with Acceptable Toxicity and Preserved Quality of Life","volume":"104","author":"Greil","year":"2019","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic Stem-Cell Transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.bbmt.2013.06.001","article-title":"Multicenter Analyses Demonstrate Significant Clinical Effects of Minor Histocompatibility Antigens on GvHD and GvL after HLA-Matched Related and Unrelated Hematopoietic Stem Cell Transplantation","volume":"19","author":"Spierings","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.humimm.2006.03.012","article-title":"Minor Histocompatibility Antigens: From Transplantation Problems to Therapy of Cancer","volume":"67","author":"Goulmy","year":"2006","journal-title":"Hum. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/bmt.2015.256","article-title":"Minor Histocompatibility Ags: Identification Strategies, Clinical Results and Translational Perspectives","volume":"51","author":"Oostvogels","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1182\/blood-2009-10-248997","article-title":"Therapy of Relapsed Leukemia after Allogeneic Hematopoietic Cell Transplantation with T Cells Specific for Minor Histocompatibility Antigens","volume":"115","author":"Warren","year":"2010","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/bmt.2017.118","article-title":"A Phase I\/II Minor Histocompatibility Antigen-Loaded Dendritic Cell Vaccination Trial to Safely Improve the Efficacy of Donor Lymphocyte Infusions in Myeloma","volume":"52","author":"Franssen","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/bmt.2016.250","article-title":"Efficacy of Host-Dendritic Cell Vaccinations with or without Minor Histocompatibility Antigen Loading, Combined with Donor Lymphocyte Infusion in Multiple Myeloma Patients","volume":"52","author":"Oostvogels","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/asheducation-2016.1.521","article-title":"Cellular and Vaccine Immunotherapy for Multiple Myeloma","volume":"2016","author":"Garfall","year":"2016","journal-title":"Hematol. Am. Soc. Hematol Educ. Program."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1158\/1078-0432.CCR-13-0282","article-title":"Vaccination with Dendritic Cell\/Tumor Fusions Following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients","volume":"19","author":"Rosenblatt","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00262-013-1438-2","article-title":"Immunogenicity of Dendritic Cells Pulsed with MAGE3, Survivin and B-Cell Maturation Antigen MRNA for Vaccination of Multiple Myeloma Patients","volume":"62","author":"Hobo","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","article-title":"Dendritic-Cell-Based Therapeutic Cancer Vaccines","volume":"39","author":"Palucka","year":"2013","journal-title":"Immunity"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1034\/j.1600-065X.2002.18813.x","article-title":"GM-CSF-Based Cancer Vaccines","volume":"188","author":"Dranoff","year":"2002","journal-title":"Immunol. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1182\/blood.V126.23.4238.4238","article-title":"Allogeneic Myeloma GVAX with Lenalidomide Enhances Progression Free Survival through the Generation of Tumor Specific Immunity in Patients in Near Complete Remission","volume":"126","author":"Borrello","year":"2015","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.omtm.2017.03.004","article-title":"Dendritic Cell Therapies for Hematologic Malignancies","volume":"5","author":"Weinstock","year":"2017","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fonc.2021.624742","article-title":"Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"11","author":"Wong","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e183267","DOI":"10.1001\/jamaoncol.2018.3267","article-title":"Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial","volume":"4","author":"Nooka","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the Development of Personalized Neoantigen-Based Therapeutic Cancer Vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An Immunogenic Personal Neoantigen Vaccine for Patients with Melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen Vaccine Generates Intratumoral T Cell Responses in Phase Ib Glioblastoma Trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/1078-0432.CCR-19-2309","article-title":"Mutation-Derived Neoantigen-Specific T-Cell Responses in Multiple Myeloma","volume":"26","author":"Perumal","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrclinonc.2011.116","article-title":"Cell Transfer Immunotherapy for Metastatic Solid Cancer\u2014What Clinicians Need to Know","volume":"8","author":"Rosenberg","year":"2011","journal-title":"Nat. Rev. Clin. Oncol"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.1073\/pnas.202491499","article-title":"T Cells from the Tumor Microenvironment of Patients with Progressive Myeloma Can Generate Strong, Tumor-Specific Cytolytic Responses to Autologous, Tumor-Loaded Dendritic Cells","volume":"99","author":"Dhodapkar","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/0008-5472.CAN-04-3337","article-title":"Activated Marrow-Infiltrating Lymphocytes Effectively Target Plasma Cells and Their Clonogenic Precursors","volume":"65","author":"Noonan","year":"2005","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1158\/1078-0432.CCR-14-0433","article-title":"Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions","volume":"20","author":"Lu","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of Mutational Processes in Human Cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational Heterogeneity in Cancer and the Search for New Cancer-Associated Genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"288ra78","DOI":"10.1126\/scitranslmed.aaa7014","article-title":"Adoptive Transfer of Activated Marrow-Infiltrating Lymphocytes Induces Measurable Antitumor Immunity in the Bone Marrow in Multiple Myeloma","volume":"7","author":"Noonan","year":"2015","journal-title":"Sci Transl Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","article-title":"Low and Variable Tumor Reactivity of the Intratumoral TCR Repertoire in Human Cancers","volume":"25","author":"Scheper","year":"2019","journal-title":"Nat. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3389\/fonc.2020.01347","article-title":"The Ways of Isolating Neoantigen-Specific T Cells","volume":"10","author":"Li","year":"2020","journal-title":"Front. Oncol"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2000.18.16.3031","article-title":"Donor Lymphocyte Infusions for Relapsed Multiple Myeloma After Allogeneic Stem-Cell Transplantation: Predictive Factors for Response and Long-Term Outcome","volume":"18","author":"Lokhorst","year":"2000","journal-title":"JCO"},{"key":"ref_65","first-page":"1525","article-title":"Durable Responses after Donor Lymphocyte Infusion for Patients with Residual Multiple Myeloma Following Non-Myeloablative Allogeneic Stem Cell Transplant","volume":"53","author":"Beitinjaneh","year":"2012","journal-title":"null"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3389\/fimmu.2017.00465","article-title":"Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation","volume":"8","author":"Simonetta","year":"2017","journal-title":"Front. Immunol"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human Natural Killer Cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12032-007-0007-y","article-title":"Clinical Stage-Depending Decrease of NK Cell Activity in Multiple Myeloma Patients","volume":"24","author":"Jurisic","year":"2007","journal-title":"Med. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.leu.2404096","article-title":"Impaired Activating Receptor Expression Pattern in Natural Killer Cells from Patients with Multiple Myeloma","volume":"20","author":"Fauriat","year":"2006","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/imm.12082","article-title":"Differential Expression of Natural Killer Cell Activating Receptors in Blood versus Bone Marrow in Patients with Monoclonal Gammopathy","volume":"139","author":"Costello","year":"2013","journal-title":"Immunology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2141.2008.07340.x","article-title":"Infusion of Haplo-Identical Killer Immunoglobulin-like Receptor Ligand Mismatched NK Cells for Relapsed Myeloma in the Setting of Autologous Stem Cell Transplantation","volume":"143","author":"Shi","year":"2008","journal-title":"Br. J. Haematol"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/ng2077","article-title":"Global Diversity and Evidence for Coevolution of KIR and HLA","volume":"39","author":"Single","year":"2007","journal-title":"Nat. Genet."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful Adoptive Transfer and in Vivo Expansion of Human Haploidentical NK Cells in Patients with Cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-Versus-Myeloma Effect: Proof of Principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I Study of Cord Blood-Derived Natural Killer Cells Combined with Autologous Stem Cell Transplantation in Multiple Myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br. J. Haematol"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2018.36.15_suppl.8006","article-title":"Phase II Study of Ex Vivo Expanded Cord Blood Natural Killer Cells for Multiple Myeloma","volume":"36","author":"Shah","year":"2018","journal-title":"JCO"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bjh.14866","article-title":"Activity of Lenalidomide in Mantle Cell Lymphoma Can Be Explained by NK Cell-Mediated Cytotoxicity","volume":"179","author":"Hagner","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1182\/blood-2010-04-278432","article-title":"The Immunostimulatory Effect of Lenalidomide on NK-Cell Function Is Profoundly Inhibited by Concurrent Dexamethasone Therapy","volume":"117","author":"Hsu","year":"2011","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of Daratumumab on Natural Killer Cells and Impact on Clinical Outcomes in Relapsed or Refractory Multiple Myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood.2020006200","article-title":"CD38 Deletion of Human Primary NK Cells Eliminates Daratumumab-Induced Fratricide and Boosts Their Effector Activity","volume":"136","author":"Nagai","year":"2020","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive Cell Transfer as Personalized Immunotherapy for Human Cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Albinger, N., Hartmann, J., and Ullrich, E. (2021). Current Status and Perspective of CAR-T and CAR-NK Cell Therapy Trials in Germany. Gene Ther.","DOI":"10.1038\/s41434-021-00246-w"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Bishop, D.C., Clancy, L.E., Simms, R., Burgess, J., Mathew, G., Moezzi, L., Street, J.A., Sutrave, G., Atkins, E., and McGuire, H.M. (2021). Development of CAR T-Cell Lymphoma in Two of Ten Patients Effectively Treated with PiggyBac Modified CD19 CAR T-Cells. Blood.","DOI":"10.1182\/blood.2021010813"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene Therapy with Human and Mouse T-Cell Receptors Mediates Cancer Regression and Targets Normal Tissues Expressing Cognate Antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 Antibodies in Multiple Myeloma: Back to the Future","volume":"131","author":"Richardson","year":"2018","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41423-019-0355-5","article-title":"Efficiency and Side Effects of Anti-CD38 CAR T Cells in an Adult Patient with Relapsed B-ALL after Failure of Bi-Specific CD19\/CD22 CAR T Cell Treatment","volume":"17","author":"Guo","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1\u2013Specific TCR\u2013Engineered T Cells Mediate Sustained Antigen-Specific Antitumor Effects in Myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-Engineered T Cells in Patients with Refractory Cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor Antigen Escape from CAR T-Cell Therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA Is Essential for the Survival of Long-Lived Bone Marrow Plasma Cells","volume":"199","author":"Raman","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","article-title":"CAR T-Cell Therapy for Multiple Myeloma: State of the Art and Prospects","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-Cell Therapy in Multiple Myeloma: More Room for Improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"(2021). First CAR-T Therapy to Target BCMA Gets FDA Nod. Nat. Biotechnol., 39, 531.","DOI":"10.1038\/s41587-021-00929-0"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b\/2 Open-Label Study","volume":"398","author":"Berdeja","year":"2021","journal-title":"The Lancet"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA Gene Deletion in Response to Anti-BCMA CAR T Cells in a Patient with Multiple Myeloma","volume":"27","author":"Dietrich","year":"2021","journal-title":"Nat. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-139040","article-title":"Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma","volume":"136","author":"Samur","year":"2020","journal-title":"Blood"},{"key":"ref_102","first-page":"372","article-title":"Mechanisms of Resistance to CAR T Cell Therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/imcb.12254","article-title":"Chimeric Antigen Receptor T Cell Persistence and Memory Cell Formation","volume":"97","author":"McLellan","year":"2019","journal-title":"Immunol. Cell Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically Optimized BCMA\/CS1 Bispecific CAR-T Cells Robustly Control Heterogeneous Multiple Myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an Optimal Dual-Targeted CAR T-Cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape\u2013Driven Relapse in Multiple Myeloma","volume":"1","author":"Staehr","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational Design of a Trimeric APRIL-Based CAR-Binding Domain Enables Efficient Targeting of Multiple Myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3324\/haematol.2019.245969","article-title":"Excellent Proliferation and Persistence of Allogeneic Donor-Derived 41-BB Based CAR-T Cells despite Immunosuppression with Cyclosporine A","volume":"105","author":"Ayuk","year":"2020","journal-title":"Haematologica"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-Shelf\u2019 Allogeneic CAR T Cells: Development and Challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fimmu.2017.00533","article-title":"Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity","volume":"8","author":"Zhang","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Wrona, E., Borowiec, M., and Potemski, P. (2021). CAR-NK Cells in the Treatment of Solid Tumors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115899"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","article-title":"Identification of Cereblon-Binding Proteins and Relationship with Response and Survival after IMiDs in Multiple Myeloma","volume":"124","author":"Zhu","year":"2014","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells","volume":"343","author":"Udeshi","year":"2014","journal-title":"Science"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.3389\/fimmu.2018.02987","article-title":"Regulation of Effector and Memory CD8 T Cell Differentiation by IL-2\u2014A Balancing Act","volume":"9","author":"Kalia","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2016-07-729236","article-title":"Phase 1\/2 Study of Lenalidomide Combined with Low-Dose Cyclophosphamide and Prednisone in Lenalidomide-Refractory Multiple Myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","article-title":"Metronomic Chemotherapy: New Rationale for New Directions","volume":"7","author":"Pasquier","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/mt.2011.113","article-title":"Immunological Effects of Low-Dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus","volume":"19","author":"Cerullo","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00262-011-1106-3","article-title":"Metronomic Cyclophosphamide Treatment in Metastasized Breast Cancer Patients: Immunological Effects and Clinical Outcome","volume":"61","author":"Ge","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/eji.200324181","article-title":"CD4+CD25+ Regulatory T\u2004Cells Suppress Tumor Immunity but Are Sensitive to Cyclophosphamide Which Allows Immunotherapy of Established Tumors to Be Curative","volume":"34","author":"Ghiringhelli","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1158\/0008-5472.CAN-10-0283","article-title":"Selective Depletion of CD4+CD25+Foxp3+ Regulatory T Cells by Low-Dose Cyclophosphamide Is Explained by Reduced Intracellular ATP Levels","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fcell.2019.00050","article-title":"Immunogenic Cell Death and Immunotherapy of Multiple Myeloma","volume":"7","author":"Anel","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fcell.2019.00149","article-title":"Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma","volume":"7","author":"Maes","year":"2019","journal-title":"Front. Cell Dev. Biol"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Gulla, A., Morelli, E., Samur, M.K., Botta, C., Hideshima, T., Bianchi, G., Fulciniti, M., Malvestiti, S., Prabhala, R.H., and Talluri, S. (2021). Bortezomib Induces Anti\u2013Multiple Myeloma Immune Response Mediated by CGAS\/STING Pathway Activation. Blood Cancer Discov.","DOI":"10.1158\/2643-3230.BCD-21-0047"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"bcr2016215237","DOI":"10.1136\/bcr-2016-215237","article-title":"Long-Term Survival Consequent on the Abscopal Effect in a Patient with Multiple Myeloma","volume":"2016","author":"Saba","year":"2016","journal-title":"BMJ Case Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2217\/fon-2020-0994","article-title":"The Abscopal Effect of Radiation Therapy","volume":"17","author":"Craig","year":"2021","journal-title":"Future Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 Expression and Complement Inhibitors Affect Response and Resistance to Daratumumab Therapy in Myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1158\/1078-0432.CCR-17-2027","article-title":"Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab","volume":"23","author":"Krejcik","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"33621","DOI":"10.18632\/oncotarget.26098","article-title":"Trogocytosis Represents a Novel Mechanism of Action of Daratumumab in Multiple Myeloma","volume":"9","author":"Krejcik","year":"2018","journal-title":"Oncotarget"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Plesner, T., van de Donk, N., and Richardson, P.G. (2020). Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?. Cells, 9.","DOI":"10.3390\/cells9020378"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/2159-8290.CD-17-1033","article-title":"CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1\/PD-L1 Blockade","volume":"8","author":"Chen","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/nyas.12485","article-title":"Unraveling the Contribution of Ectoenzymes to Myeloma Life and Survival in the Bone Marrow Niche","volume":"1335","author":"Quarona","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab Depletes CD38+ Immune Regulatory Cells, Promotes T-Cell Expansion, and Skews T-Cell Repertoire in Multiple Myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood.2020008209","article-title":"Isatuximab as Monotherapy and Combined with Dexamethasone in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"137","author":"Dimopoulos","year":"2021","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41375-019-0536-3","article-title":"In Vivo Vaccination Effect in Multiple Myeloma Patients Treated with the Monoclonal Antibody Isatuximab","volume":"34","author":"Atanackovic","year":"2020","journal-title":"Leukemia"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Costa, F., Marchica, V., Storti, P., Malavasi, F., and Giuliani, N. (2021). PD-L1\/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression. Cancers, 13.","DOI":"10.3390\/cancers13020164"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 Axis Modulates the Natural Killer Cell versus Multiple Myeloma Effect: A Therapeutic Target for CT-011, a Novel Monoclonal Anti\u2013PD-1 Antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma","volume":"21","author":"Samur","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2016-08-731885","article-title":"Targeting the PD-1\/PD-L1 Axis in Multiple Myeloma: A Dream or a Reality?","volume":"129","author":"Rosenblatt","year":"2017","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Verkleij, C.P.M., Jhatakia, A., Broekmans, M.E.C., Frerichs, K.A., Zweegman, S., Mutis, T., Bezman, N.A., and van de Donk, N.W.C.J. (2020). Preclinical Rationale for Targeting the PD-1\/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies. Cancers (Basel), 12.","DOI":"10.3390\/cancers12123713"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.clml.2020.08.008","article-title":"Daratumumab With Cetrelimab, an Anti\u2013PD-1 Monoclonal Antibody, in Relapsed\/Refractory Multiple Myeloma","volume":"21","author":"Cohen","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1200\/JCO.2016.34.15_suppl.8010","article-title":"Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed\/Refractory Multiple Myeloma (RRMM): Final Efficacy and Safety Analysis","volume":"34","author":"Mateos","year":"2016","journal-title":"JCO"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-020-00350-x","article-title":"Immune-Based Therapies in the Management of Multiple Myeloma","volume":"10","author":"Zanwar","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus Pomalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (KEYNOTE-183): A Randomised, Open-Label, Phase 3 Trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus Lenalidomide and Dexamethasone for Patients with Treatment-Naive Multiple Myeloma (KEYNOTE-185): A Randomised, Open-Label, Phase 3 Trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_146","unstructured":"(2021, June 23). Genmab Announces That Janssen Will Stop Studies of Daratumumab in Combination with Anti-PD-(L)1 - Genmab A\/S. Available online: https:\/\/ir.genmab.com\/news-releases\/news-release-details\/genmab-announces-janssen-will-stop-studies-daratumumab."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy of Chronic Lymphocytic Leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jcyt.2018.07.005","article-title":"Programmed Cell Death Protein 1 Activation Preferentially Inhibits CD28.CAR\u2013T Cells","volume":"20","author":"Zolov","year":"2018","journal-title":"Cytotherapy"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2017.35.15_suppl.3025","article-title":"Characterization of Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell-Mediated Tumor Microenvironment Immune Gene Profile in a Multicenter Trial (ZUMA-1) with Axicabtagene Ciloleucel (Axi-Cel, KTE-C19)","volume":"35","author":"Galon","year":"2017","journal-title":"JCO"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood-2018-99-119514","article-title":"PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed\/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells","volume":"132","author":"Bernabei","year":"2018","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/hematology.2020000111","article-title":"Future of CAR T Cells in Multiple Myeloma","volume":"2020","author":"Wudhikarn","year":"2020","journal-title":"Hematol. Am. Soc. Hematol Educ Program."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"34341","DOI":"10.18632\/oncotarget.9114","article-title":"Chimeric Antigen Receptor T Cells Secreting Anti-PD-L1 Antibodies More Effectively Regress Renal Cell Carcinoma in a Humanized Mouse Model","volume":"7","author":"Suarez","year":"2016","journal-title":"Oncotarget"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted Delivery of a PD-1-Blocking ScFv by CAR-T Cells Enhances Anti-Tumor Efficacy in Vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1038\/s41598-018-23803-7","article-title":"Genetic Abrogation of Immune Checkpoints in Antigen-Specific Cytotoxic T-Lymphocyte as a Potential Alternative to Blockade Immunotherapy","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin\u2019s Lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 Antibody\u2013Mediated Phagocytosis of Cancer by Macrophages Primes an Effective Antitumor T-Cell Response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.16548","article-title":"CD14+CD16+ Monocytes Are Involved in Daratumumab-Mediated Myeloma Cells Killing and in Anti-CD47 Therapeutic Strategy","volume":"190","author":"Storti","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3389\/fimmu.2019.00453","article-title":"Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma","volume":"10","author":"Khair","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Zhou, X., Einsele, H., and Danhof, S. (2020). Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072166"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The Making of Bispecific Antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti\u2013B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"JCO"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.18632\/oncotarget.27792","article-title":"T-Cell Redirecting Bispecific Antibodies Targeting BCMA for the Treatment of Multiple Myeloma","volume":"11","author":"Verkleij","year":"2020","journal-title":"Oncotarget"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical Activity of JNJ-7957, a Novel BCMA\u00d7CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood-2018-99-118425","article-title":"Anti-BCMA BiTE\u00ae AMG 701 Potently Induces Specific T Cell Lysis of Human Multiple Myeloma (MM) Cells and Immunomodulation in the Bone Marrow Microenvironment","volume":"132","author":"Cho","year":"2018","journal-title":"Blood"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5\/CD3 and Is a Requirement for Myeloma Cell Killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2019-131061","article-title":"Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504","volume":"134","author":"Schwartz","year":"2019","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41375-018-0014-3","article-title":"Simultaneous Multiple Interaction T-Cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-Cell Engager (BiTE) Resistance via CD28 Co-Stimulation","volume":"32","author":"Correnti","year":"2018","journal-title":"Leukemia"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific Antibodies Enhance the Therapeutic Efficacy of Tumor-Directed T Cells through T Cell Receptor Co-Stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1158\/1538-7445.AM2020-5641","article-title":"Abstract 5641: CD28 Expression on Multiple Myeloma Cells Enhances the Cytotoxic Activity of CD38\/CD28xCD3 Trispecific T Cell Engager","volume":"80","author":"Henry","year":"2020","journal-title":"Cancer Res."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1038\/s41467-019-13196-0","article-title":"On-Target Restoration of a Split T Cell-Engaging Antibody for Precision Immunotherapy","volume":"10","author":"Banaszek","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Weidanz, J. (2021). Targeting Cancer with Bispecific Antibodies. Science, eabg5568.","DOI":"10.1126\/science.abg5568"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Hsiue, E.H.-C., Wright, K.M., Douglass, J., Hwang, M.S., Mog, B.J., Pearlman, A.H., Paul, S., DiNapoli, S.R., Konig, M.F., and Wang, Q. (2021). Targeting a Neoantigen Derived from a Common TP53 Mutation. Science, eabc8697.","DOI":"10.1126\/science.abc8697"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1200\/JCO.2017.35.15_suppl.8045","article-title":"AFM26 Is a Novel, Highly Potent BCMA\/CD16A-Directed Bispecific Antibody for High Affinity NK-Cell Engagement in Multiple Myeloma","volume":"35","author":"Gantke","year":"2017","journal-title":"JCO"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/protein\/gzx043","article-title":"Trispecific Antibodies for CD16A-Directed NK Cell Engagement and Dual-Targeting of Tumor Cells","volume":"30","author":"Gantke","year":"2017","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(71)92086-1","article-title":"REGRESSION OF BURKITT\u2019S LYMPHOMA IN ASSOCIATION WITH MEASLES INFECTION","volume":"298","author":"Bluming","year":"1971","journal-title":"Lancet"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S0140-6736(81)92286-8","article-title":"Regression of Hodgkin\u2019s Disease After Measles","volume":"317","author":"Taqi","year":"1981","journal-title":"Lancet"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1126\/science.282.5392.1332","article-title":"Reovirus Therapy of Tumors with Activated Ras Pathway","volume":"282","author":"Coffey","year":"1998","journal-title":"Science"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.exphem.2006.03.002","article-title":"Oncolytic Measles Virus Targets High CD46 Expression on Multiple Myeloma Cells","volume":"34","author":"Ong","year":"2006","journal-title":"Exp. Hematol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41408-017-0020-0","article-title":"Oncolytic Virotherapy as an Immunotherapeutic Strategy for Multiple Myeloma","volume":"7","author":"Meyers","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Calton, C.M., Kelly, K.R., Anwer, F., Carew, J.S., and Nawrocki, S.T. (2018). Oncolytic Viruses for Multiple Myeloma Therapy. Cancers, 10.","DOI":"10.3390\/cancers10060198"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1038\/s41375-020-0828-7","article-title":"Oncolytic Measles Virus Therapy Enhances Tumor Antigen-Specific T-Cell Responses in Patients with Multiple Myeloma","volume":"34","author":"Packiriswamy","year":"2020","journal-title":"Leukemia"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1182\/blood-2003-07-2233","article-title":"Image-Guided Radiovirotherapy for Multiple Myeloma Using a Recombinant Measles Virus Expressing the Thyroidal Sodium Iodide Symporter","volume":"103","author":"Dingli","year":"2004","journal-title":"Blood"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2214\/AJR.08.1205","article-title":"Quantitative Molecular Imaging of Viral Therapy for Pancreatic Cancer Using an Engineered Measles Virus Expressing the Sodium-Iodide Symporter Reporter Gene","volume":"192","author":"Carlson","year":"2009","journal-title":"AJR Am. J. Roentgenol"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/leu.2017.120","article-title":"Phase I Trial of Systemic Administration of Edmonston Strain of Measles Virus Genetically Engineered to Express the Sodium Iodide Symporter in Patients with Recurrent or Refractory Multiple Myeloma","volume":"31","author":"Dispenzieri","year":"2017","journal-title":"Leukemia"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.2021.39.15_suppl.2500","article-title":"Clinical Activity of Systemic VSV-IFN\u03b2-NIS Oncolytic Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma","volume":"39","author":"Cook","year":"2021","journal-title":"JCO"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/18\/4546\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:00:20Z","timestamp":1760166020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/18\/4546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":186,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["cancers13184546"],"URL":"https:\/\/doi.org\/10.3390\/cancers13184546","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,10]]}}}